Sanofi (SNY)
NASDAQ: SNY · Real-Time Price · USD
48.66
+0.31 (0.64%)
Feb 27, 2026, 4:00 PM EST - Market closed
Sanofi Revenue
In the year 2025, Sanofi had annual revenue of 46.72B EUR with 5.49% growth. Sanofi had revenue of 12.21B in the quarter ending December 31, 2025.
Revenue (ttm)
46.72B EUR
Revenue Growth
+5.49%
P/S Ratio
2.14
Revenue / Employee
624,162 EUR
Employees
74,846
Market Cap
117.29B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 46.72B | 2.43B | 5.49% |
| Dec 31, 2024 | 44.29B | 3.18B | 7.73% |
| Dec 31, 2023 | 41.11B | 805.00M | 2.00% |
| Dec 31, 2022 | 40.30B | 1.13B | 2.88% |
| Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Merck & Co. | 65.01B |
| Pfizer | 62.58B |
| AbbVie | 61.16B |
| AstraZeneca | 58.74B |
| Novartis AG | 56.67B |
| Novo Nordisk | 48.59B |
| Bristol-Myers Squibb Company | 48.19B |
| GSK plc | 43.97B |
SNY News
- 1 day ago - Sanofi (SNY) and Regeneron (REGN) Gain EMA Nod for Dupixent Expansion - GuruFocus
- 1 day ago - Regeneron, Sanofi Receive Positive CHMP Opinion For Dupixent In Pediatric CSU - Nasdaq
- 1 day ago - Sanofi (SNY): Positive EMA Opinion for Dupixent Approval in the EU - GuruFocus
- 1 day ago - Sanofi: Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment - Finanz Nachrichten
- 1 day ago - Press Release: Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment - Benzinga
- 1 day ago - Press Release: Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment - GlobeNewsWire
- 1 day ago - Sanofi's Acoziborole Receives Positive CHMP Opinion For Sleeping Sickness Treatment - Finanz Nachrichten
- 1 day ago - Sanofi: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness - Finanz Nachrichten